Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe

PHASE3CompletedINTERVENTIONAL
Enrollment

1,660

Participants

Timeline

Start Date

December 14, 2018

Primary Completion Date

May 17, 2023

Study Completion Date

May 24, 2023

Conditions
Meningococcal Infections
Interventions
BIOLOGICAL

MenACYW conjugate vaccine

Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid conjugate vaccine, 0.5 mL, intramuscular

BIOLOGICAL

Meningococcal group A, C, W-135, and Y conjugate vaccine

Meningococcal group A, C, W-135, and Y conjugate vaccine, 0.5 mL, intramuscular

BIOLOGICAL

DTaP-IPV-HB-Hib vaccine

Diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and Haemophilus influenzae type b vaccine

BIOLOGICAL

Pneumococcal vaccine (13-valent)

Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed)

BIOLOGICAL

Pneumococcal vaccine (10-valent)

Pneumococcal polysaccharide conjugate vaccine (10-valent, adsorbed)

BIOLOGICAL

MMR vaccine

Measles, mumps, and rubella vaccine

Trial Locations (33)

15706

Investigational Site Number : 7245001, Santiago de Compostela

20122

Investigational Site Number : 3803002, Milan

20520

Investigational Site Number : 2462008, Turku

21105

Investigational Site Number : 6424001, Bucaresti

28007

Investigational Site Number : 7245003, Madrid

28046

Investigational Site Number : 7245002, Madrid

28100

Investigational Site Number : 2462002, Pori

33100

Investigational Site Number : 2462010, Tampere

34401

Investigational Site Number : 2031013, Domažlice

41014

Investigational Site Number : 7245006, Seville

60100

Investigational Site Number : 2462009, Seinäjoki

67100

Investigational Site Number : 2462006, Kokkola

90220

Investigational Site Number : 2462005, Oulu

235200

Investigational Site Number : 6424006, Caracal

500063

Investigational Site Number : 6424003, Brasov

910160

Investigational Site Number : 6424002, Călăraşi

503 51

Investigational Site Number : 2031006, Chlumec nad Cidlinou

377 01

Investigational Site Number : 2031010, Jindřichův Hradec

Investigational Site Number : 2031012, Jindřichův Hradec

702 00

Investigational Site Number : 2031003, Ostrava

700 30

Investigational Site Number : 2031008, Ostrava-hrabuvka

530 09

Investigational Site Number : 2031009, Pardubice

530 12

Investigational Site Number : 2031005, Pardubice

503 03

Investigational Site Number : 2031007, Smiřice

02230

Investigational Site Number : 2462007, Espoo

00100

Investigational Site Number : 2462003, Helsinki

00930

Investigational Site Number : 2462004, Helsinki

04400

Investigational Site Number : 2462001, Järvenpää

85-090

Investigational Site Number : 6167002, Bydgoszcz

55-100

Investigational Site Number : 6167004, Trzebnica

41-103

Investigational Site Number : 6167003, Siemianowice Śląskie

87-100

Investigational Site Number : 6167006, Torun

901 87

Investigational Site Number : 7526001, Umeå

All Listed Sponsors
lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT03547271 - Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe | Biotech Hunter | Biotech Hunter